Head Immunology Section, Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón (HGUGM), 28007, Madrid, Spain.
Spanish HIV-HGM BioBank, 28007, Madrid, Spain.
J Nanobiotechnology. 2022 Mar 21;20(1):151. doi: 10.1186/s12951-022-01350-8.
The absence of an effective treatment and vaccine in HIV-1 pandemic place preventive strategies such as safety and effective microbicide development as a central therapeutic approach to control HIV-1 pandemic nowadays.
Studies of cytotoxicity, immune population status, inflammation or tissue damage and mainly prophylactic inhibition of HIV-1 infection in vaginal human explants demonstrate the biosafety and effectivity of G2-S16 dendrimer. Human explants treated with G2-S16 dendrimer or treated and HIV-1 infected do not presented signs of irritation, inflammation, immune activation or T cell populations deregulation.
Herein we conclude that G2-S16 dendrimer has demonstrated sufficient efficacy, biosafety, effectivity and behavior in the closest to the real-life condition model represented by the human healthy donor vaginal tissue explants, to raise G2-S16 dendrimer as a promising candidate to clinical trials to develop an effective microbicide against HIV-1 infection.
在 HIV-1 大流行中，缺乏有效的治疗和疫苗，因此预防策略，如安全有效的杀微生物剂的开发，成为当今控制 HIV-1 大流行的重要治疗方法。
对细胞毒性、免疫人群状况、炎症或组织损伤的研究，以及主要对阴道人组织外植体中 HIV-1 感染的预防性抑制，证明了 G2-S16 树突的生物安全性和有效性。用 G2-S16 树突处理或处理后感染 HIV-1 的人组织外植体没有表现出刺激、炎症、免疫激活或 T 细胞群失调的迹象。
在此，我们得出结论，G2-S16 树突在由健康供体阴道组织外植体代表的最接近真实生活条件的模型中表现出足够的疗效、生物安全性、有效性和行为，将 G2-S16 树突作为一种有前途的候选药物，用于开发针对 HIV-1 感染的有效杀微生物剂的临床试验。
